Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. Fundamental Analysis
Collegium Pharmaceutical, Inc. (COLL) shows moderate financial fundamentals with a PE ratio of 24.26, profit margin of 7.72%, and ROE of 24.09%. The company generates $0.8B in annual revenue with strong year-over-year growth of 11.41%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 57.7/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze COLL's fundamental strength across five key dimensions:
Efficiency Score
WeakCOLL struggles to generate sufficient returns from assets.
Valuation Score
ExcellentCOLL trades at attractive valuation levels.
Growth Score
ExcellentCOLL delivers strong and consistent growth momentum.
Financial Health Score
ModerateCOLL shows balanced financial health with some risks.
Profitability Score
ModerateCOLL maintains healthy but balanced margins.
Key Financial Metrics
Is COLL Expensive or Cheap?
P/E Ratio
COLL trades at 24.26 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, COLL's PEG of 0.43 indicates potential undervaluation.
Price to Book
The market values Collegium Pharmaceutical, Inc. at 5.16 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 1.66 times EBITDA. This is generally considered low.
How Well Does COLL Make Money?
Net Profit Margin
For every $100 in sales, Collegium Pharmaceutical, Inc. keeps $7.72 as profit after all expenses.
Operating Margin
Core operations generate 20.94 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $24.09 in profit for every $100 of shareholder equity.
ROA
Collegium Pharmaceutical, Inc. generates $3.64 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Collegium Pharmaceutical, Inc. generates strong operating cash flow of $291.28M, reflecting robust business health.
Free Cash Flow
Collegium Pharmaceutical, Inc. generates strong free cash flow of $289.66M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $9.16 in free cash annually.
FCF Yield
COLL converts 20.44% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
24.26
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.43
vs 25 benchmark
P/B Ratio
Price to book value ratio
5.16
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.88
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
3.41
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.36
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.24
vs 25 benchmark
ROA
Return on assets percentage
0.04
vs 25 benchmark
ROCE
Return on capital employed
0.14
vs 25 benchmark
How COLL Stacks Against Its Sector Peers
| Metric | COLL Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 24.26 | 29.28 | Better (Cheaper) |
| ROE | 24.09% | 820.00% | Weak |
| Net Margin | 7.72% | -19743.00% (disorted) | Weak |
| Debt/Equity | 3.41 | 0.26 | Weak (High Leverage) |
| Current Ratio | 1.36 | 4.69 | Neutral |
| ROA | 3.64% | -17807.00% (disorted) | Weak |
COLL outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Collegium Pharmaceutical, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
120.60%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
980.21%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
664.76%
Industry Style: Defensive, Growth, Innovation
High Growth